Stephens & Co. Maintains Equal-Weight on Lifecore Biomedical, Raises Price Target to $9
Lifecore Biomedical Analyst Ratings
Barrington Trims Price Target on Lifecore Biomedical to $10 From $11, Maintains Outperform Rating
Barrington Raises Price Target on Lifecore Biomedical to $11 From $10, Keeps Outperform Rating
Barrington Keeps Their Buy Rating on Lifecore Biomedical (LFCR)
Barrington Remains a Buy on Lifecore Biomedical (LFCR)
Analyst Ratings for Lifecore Biomedical
Barrington Research Maintains Outperform on Lifecore Biomedical, Lowers Price Target to $8
Barrington Cuts Price Target on Lifecore Biomedical to $8 From $10, Keeps Outperform Rating
Stephens & Co. Downgrades Lifecore Biomedical to Equal-Weight, Lowers Price Target to $2
Analysts Offer Insights on Healthcare Companies: Lifecore Biomedical (LFCR), Prestige Consumer Healthcare (PBH) and Quest Diagnostics (DGX)
Stephens & Co. Reiterates Overweight on Lifecore Biomedical, Maintains $11 Price Target
Landec Analyst Ratings
Barrington Research Maintains Outperform on Landec, Lowers Price Target to $12
Barrington Research Lowers Landec's Price Target to $12 From $14, Maintains Outperform Rating
Barrington Sticks to Its Buy Rating for Landec (LNDC)
Barrington Sticks to Their Buy Rating for Landec (LNDC)
Landec Price Target Announced at $14.00/Share by Barrington Research
Landec Raised to Outperform From Market Perform by Barrington Research
Landec analyst ratings
No Data